This article is more than 5 years old. Information may no longer be current.

Avedro gains CE mark for riboflavin formulations

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

Avedro has received CE mark approval for its newest riboflavin formulations, according to a press release.

The new formulations are designed for use in conjunction with Avedro’s KXL system.

The ParaCel formulation for transepithelial cross-linking is based on research and an associated patent by Roberto Pinelli, MD, director of the Istituto Laser Microchirurgia Oculare, the release said.

“ParaCel provides for an easier, faster and more comfortable cross-linking procedure when treating my keratoconic and ectasia patients,” Pinelli said in the release. “When using ParaCel in combination with Avedro’s KXL system, I am able to treat my keratoconic patients in a much shorter time, without the postoperative discomfort associated with removal of the epithelium.”

Avedro is currently sponsoring phase 3 corneal collagen cross-linking trials in the U.S.